
TSE:WELL
This summary was created by AI, based on 13 opinions in the last 12 months.
WELL Health Technologies is perceived as a company with potential, particularly given its focus on electronic medical records and clinic operations. Reviews highlight a recent struggle with execution, particularly post-pandemic, and frustrations related to acquisitions that haven't significantly moved the stock price. Analysts note a divergent sentiment towards the stock, with many awaiting catalysts for a price rebound, especially as they divest from less favorable US operations. Despite impressive revenue growth signals and an attractive valuation at around 9-10x PE, concerns over competition and regulatory scrutiny remain prevalent, leaving experts in a cautious wait-and-see mode about the company's longer-term prospects.
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The fundamental outlook has not changed. Their acquisition from 2021 is still to be proven. Sentiment is shifting towards telehealth with covid being less of a concern. Revenu growth should be good in 2022. The company is moving closer to profitability. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The entire sector has been weak. Investors have some reservations about dilution from the aggressive acquisition strategy. Still comfortable with the stock in the longer term. Unlock Premium - Try 5i Free
Telehealth player, with more of an unfocused strategy. Whereas AKU is very focused.
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. No concerns for the stock except for the short term volatility. The short report will affect it short term, but management is committed with no sellers. Insiders own 16%. Attractive around $5.75. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. They are in the midst of acquiring CRH. They will have more than $300M sales. Including expected growth, it looks much cheaper than it is. The company has lost money to date but is expected to make a profit this year. It must execute and is not risk free. Good growth potential. Unlock Premium - Try 5i Free
WELL vs. TDOC He likes the industry, especially during Covid. A lot of efficiency gains have been unlocked with telehealth platforms. He prefers TDOC in the US, especially after its recent integration.
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The market has shifted quickly recently. However, with an appropriate time frame, this stock should do fine. Nothing has changed fundamentally or at the company level. Though not risk free, the drop is market-related and not fundamental issues with the company. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The acquisition of CRH is expected to be highly synergistic. There will be cross selling opportunities and a substantial presence in the US. It will attract new investors as it gets bigger. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The US listing is generally positive. The move to be on the US index makes sense for a high growth company. Investors in the US are fine paying up front for future growth. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The stock price should not go below $3. 5i did not expect shares to go this low. Investors are not reacting to fundamentals recently. Nothing has changed for the company. More acquisitions should happen. Management is following their 5 year plan and doing a good job. Unlock Premium - Try 5i Free